Analysts at Goldman Sachs Group assumed coverage on shares of Odonate Therapeutics (NASDAQ:ODT) in a note issued to investors on Tuesday, January 2nd, MarketBeat Ratings reports. The firm set a “neutral” rating and a $27.00 price target on the stock. Goldman Sachs Group’s price objective would suggest a potential upside of 24.48% from the stock’s previous close.
A number of other research firms have also weighed in on ODT. Cowen started coverage on Odonate Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating on the stock. Jefferies Group started coverage on Odonate Therapeutics in a research note on Tuesday, January 2nd. They set a “buy” rating and a $40.00 price objective on the stock.
Odonate Therapeutics (NASDAQ:ODT) traded down $0.33 during midday trading on Tuesday, reaching $21.69. The company’s stock had a trading volume of 51,419 shares, compared to its average volume of 27,988. Odonate Therapeutics has a one year low of $21.42 and a one year high of $25.36.
In other Odonate Therapeutics news, CEO Kevin C. Tang purchased 1,291,666 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were acquired at an average price of $24.00 per share, with a total value of $30,999,984.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Boxer Capital, Llc purchased 416,666 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $24.00 per share, for a total transaction of $9,999,984.00. The disclosure for this purchase can be found here. Insiders have acquired 1,709,332 shares of company stock worth $41,023,268 in the last three months.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/28/odonate-therapeutics-odt-now-covered-by-analysts-at-goldman-sachs-group.html.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.